Literature DB >> 29577637

Patient's perspective on long-term complications after superficial parotidectomy for benign lesions: Prospective analysis of a 2-year follow-up.

P Wolber1, G F Volk2, L Horstmann1, M Finkensieper2, S Shabli1, C Wittekindt3, J P Klussmann1, O Guntinas-Lichius2, D Beutner1,4, M Grosheva1.   

Abstract

OBJECTIVE: Evaluation of patients' perspective on long-term complications after superficial parotidectomy for benign lesions.
DESIGN: A prospective nonrandomized controlled multicenter study.
SETTING: Three university-based tertiary referral centers (Departments of Otorhinolaryngology of Cologne, Jena and Giessen; all in Germany). PARTICIPANTS: 130 adult patients, who underwent a primary superficial parotidectomy for benign tumors of the parotid gland, were consecutively included from 09/2010 to 05/2012. 61 patients completed every follow-up examination. MAIN OUTCOME MEASURES: Complications were evaluated using the validated German-language questionnaire Parotidectomy Outcome Inventory 8 at six, 12 and 24 months after surgery. Pain intensity was assessed on a numeric rating scale (NRS) at each follow-up visit.
RESULTS: At 6 months after surgery, 90% characterized hypoesthesia as the most disturbing problem, followed by fear of revision surgery (57%) and scar (56%). Facial palsy (14%) posed the minor problem. Hypoesthesia improved significantly during the follow-up period (all P < .05), but still posed a problem for 78% of the patients after 2 years. Pain, which initially bothered 53% of the patients, significantly decreased, whereas impairment due to Frey's syndrome significantly increased during the follow-up (6 vs 24 months; P = .002 and P = .001, respectively). Scar, substance loss, xerostomia, facial palsy, and anxiety affected patients with unvarying severity during the 2 years (all P > .05).
CONCLUSIONS: From patients' perspective, sensation loss posed the major subjective problem after superficial parotidectomy. Appearance of the scar, and fear of revision surgery impaired more than 50% of the patients in their daily life without significant improvement during the 2 years postoperatively. Although superficial parotidectomy is a highly standardized and safe procedure, limited parotidectomy for proven benign parotid salivary gland neoplasms is more likely to result in patients with minimal or no displeasing complications.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  benign parotid lesions; patient-reported outcome measures; postoperative complications; prospective studies; quality of life

Year:  2018        PMID: 29577637     DOI: 10.1111/coa.13104

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  5 in total

1.  A prospective study of patient-reported xerostomia-related outcomes after parotidectomy.

Authors:  Kara D Brodie; Aaron L Zebolsky; Edgar Ochoa; Patrick K Ha; Chase M Heaton; Ivan H El-Sayed; William R Ryan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-05-29

2.  New classification of branching pattern of facial nerve during parotidectomy: A cross sectional study.

Authors:  Omar Salem Khattab Alomar
Journal:  Ann Med Surg (Lond)       Date:  2021-01-14

3.  The importance of the patient's perspective in function-sparing parotid surgery for benign neoplasms: clinical reappraisal.

Authors:  Andrea Galli; Michele Tulli; Adriana Vella; Marco Familiari; Leone Giordano; Stefano Bondi; Davide Di Santo; Matteo Biafora; Mario Bussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-10       Impact factor: 2.124

4.  Long-term outcomes and quality of life following parotidectomy for benign disease.

Authors:  Michaela Plath; Matthias Sand; Carlo Cavaliere; Peter K Plinkert; Ingo Baumann; Karim Zaoui
Journal:  Acta Otorhinolaryngol Ital       Date:  2022-06       Impact factor: 2.618

5.  Variations in Facial Nerve Branches and Anatomical Landmarks for Its Trunk Identification: A Pilot Cadaveric Study in the Lithuanian Population.

Authors:  Dominykas Stankevicius; Andrej Suchomlinov
Journal:  Cureus       Date:  2019-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.